Ra Medical Systems, Inc. - RMED STOCK NEWS

Ra Medical Systems, Inc. (NYSE: RMED) has announced its participation in the Piper Sandler 32^nd Annual Health Care Conference, taking place virtually from December 1-3, 2020. The company specializes in excimer laser systems for treating vascular and dermatological diseases. Investors are invited to arrange 1x1 meetings with management through their Piper Sandler representatives. Ra Medical’s DABRA and Pharos excimer laser systems have received FDA clearance for treating chronic total occlusions and various skin conditions, respectively.

Ra Medical Systems, Inc. (NYSE: RMED) will showcase its Pharos excimer laser at the New Frontiers in Cosmetic Medicine Symposium on November 21, 2020. The Pharos system offers a topical treatment for skin disorders like psoriasis and vitiligo, presenting a lower-cost option compared to immunosuppressive agents, especially valuable during the pandemic for immunocompromised patients. Ra Medical manufactures its excimer lasers at an ISO-certified facility in Carlsbad, California, focusing on treatments for vascular and dermatological conditions.

Ra Medical Systems (NYSE: RMED) announced a 1-for-25 reverse stock split effective November 16, 2020, approved by the Board and stockholders. Following this split, approximately 2.9 million shares will be outstanding, trading under a new CUSIP number. The reverse split aims to enhance the Company's stock market position without altering shareholder rights. The Company's excimer laser systems, used for treating vascular and dermatological diseases, continue to drive their operations, manufactured in their California facility.

Ra Medical Systems, Inc. (NYSE: RMED) will participate in A.G.P.’s Virtual Healthcare Symposium on November 19, 2020. Management will engage in one-on-one meetings with interested investors. The company specializes in excimer laser systems for treating vascular and dermatological diseases. Their DABRA excimer laser system is FDA-cleared for treating chronic total occlusions, while the Pharos system targets skin conditions like psoriasis. Both systems are manufactured at their ISO-certified facility in Carlsbad, California.

Ra Medical Systems (NYSE: RMED) reported Q3 2020 net revenue of $0.9 million, down from $1.9 million in Q3 2019. The dermatology segment generated $0.8 million, a decline from $1.7 million a year earlier. Despite this, operational highlights include 13 subjects enrolled in a pivotal clinical trial for atherectomy and advancements in next-gen DABRA catheter prototypes. The company recorded a net loss of $7.8 million, improving from $17.4 million in Q3 2019. Cash and cash equivalents stood at $33.6 million as of September 30, 2020, indicating a stable liquidity position.

Ra Medical Systems (NYSE: RMED) is hosting a webcast titled The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic on December 2, 2020, from 7:00 to 8:00 p.m. ET. The event will feature Dr. Theodore J. Daly discussing the Pharos excimer laser system for psoriasis treatment. Key topics include AAD guidance on immunosuppressive agents during COVID, the impact on clinical practices, and alternative treatments. Registration is required, and an archived webcast will be available afterwards on Ra Medical's website.

Ra Medical Systems, Inc. (NYSE: RMED) has announced a one-day DABRA Summit aimed at gathering input for the next-generation DABRA catheters. Attendees include principal investigators and clinical coordinators from the DABRA pivotal atherectomy trial, focusing on product design enhancements and best practices for patient enrollment. With five clinical sites open for patient enrollment, Ra Medical is prioritizing improvements in their DABRA catheter and advancing the atherectomy trial. The DABRA system is designed to treat vascular blockages caused by lower extremity vascular disease.

Ra Medical Systems, Inc (NYSE: RMED) will announce its third quarter 2020 financial results and provide a business update on November 12, 2020, after market close. A conference call with management will follow at 1:30 PM PT (4:30 PM ET) to discuss the results and company updates. Pre-registration for the call is available, allowing participants to bypass live operators. The conference will be accessible for replay for up to 48 hours, and a webcast will be archived for 30 days.

Ra Medical Systems (NYSE: RMED) has enrolled its 10^th subject in a pivotal clinical trial evaluating the DABRA excimer laser system for treating peripheral arterial disease (PAD). Recent enrollment increased, with five clinical sites cleared to participate after previous delays due to the COVID-19 pandemic. The trial aims to enroll up to 100 patients, focusing on safety and effectiveness. The primary efficacy endpoint involves measuring the mean reduction in diameter stenosis. FDA 510(k) clearance was granted for DABRA in May 2017.